Global Clinical Trials Market Research Report to 2026 – With Accell Clinical Research, Clinipace, and Icon PLC, among others

DUBLIN, April 5, 2022 /PRNewswire/ — The “Research Report on Clinical Trials Market by Design, By Phase, By Indication, By Region – Global Forecast to 2026 – Cumulative Impact of COVID-19” report has been added to from ResearchAndMarkets.com offer.

The size of the global clinical trials market has been estimated at $29,712.55 million in 2020, is expected to reach $32,276.86 million in 2021, and is expected to grow at a CAGR of 8.96% to reach $49,745.40 million by 2026.

Market statistics:
The report provides market size analysis and forecasts for five major currencies – USD, EUR GBP, JPY and AUD. It helps organizational leaders make better decisions when currency data is readily available. In this report, the years 2018 and 2019 are considered as historical years, 2020 as the base year, 2021 as the estimated year and the years from 2022 to 2026 as the forecast period.

Segmentation and market coverage:
This research report categorizes clinical trials to forecast revenues and analyze trends in each of the following submarkets:

  • Based on the design, the market has been studied through the interventional study and the observational study. The interventional study is further investigated in an adaptive clinical trial, a non-randomized controlled trial, and a randomized controlled trial. The observational study is studied in more detail through a case-control study, a cohort study, a cross-sectional study and an ecological study.
  • On the basis of phase, the market has been studied in phase I, phase II, phase III and phase IV.
  • Based on the indication, the market has been studied on autoimmune/inflammatory, cardiovascular, CNS diseases, diabetes, infectious diseases, obesity, oncology, and pain management.
  • Based on region, the market has been studied across the Americas, Asia Pacificand Europe, Middle East & Africa. The Americas are studied in more detail through Argentina, Brazil, Canada, Mexicoand United States. United States is explored in more detail through California, Florida, Illinois, new York, Ohio, Pennsylvaniaand Texas. the Asia Pacific is explored in more detail through Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwanand Thailand. Europe, Middle East & Africa is explored in more detail through France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emiratesand UK.

Competitive Strategy Window:
The strategic competitive window analyzes the competitive landscape in terms of markets, applications and geographies to help the vendor define an alignment or match between its capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for vendors to adopt successive strategies of merger and acquisition, geographic expansion, research and development, and new product introduction strategies to execute further business expansion and growth. during a forecast period.

FPNV positioning matrix:
The FPNV Positioning Matrix evaluates and ranks vendors in the clinical trials market based on business strategy (business growth, industry coverage, financial viability, and channel support) and product satisfaction (ratio price-performance, ease-of-use, product features and customer support) that helps businesses make better decisions and better understand the competitive landscape.

Market share analysis:
The market share analysis offers the analysis of the vendors considering their contribution to the overall market. It gives the idea of ​​its revenue generation in the overall market compared to other providers in the space. It provides information on the performance of vendors in terms of revenue generation and customer base compared to others. Knowing the market share gives an idea of ​​the size and competitiveness of suppliers for the reference year. It reveals the characteristics of the market in terms of accumulation, fragmentation, dominance and merger.

The report provides information about the following pointers:
1. Market Penetration: Provides comprehensive information about the market offered by major players
2. Market Development: Provides detailed information on lucrative emerging markets and analyzes penetration in mature market segments
3. Market Diversification: Provides detailed information on new product launches, untapped geographies, recent developments and investments
4. Competitive Assessment and Intelligence: Provides a comprehensive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of key players
5. Product Development and Innovation: Provides smart insights into future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:
1. What is the market size and forecast of the global clinical trials market?
2. What are the inhibiting factors and impact of COVID-19 on the global clinical trials market during the forecast period?
3. What are the products/segments/applications/areas to invest in during the forecast period in the Global Clinical Trials Market?
4. What is the competitive strategic window for opportunities in the Global Clinical Trials Market?
5. What are the technology trends and regulatory frameworks in the global clinical trials market?
6. What is the market share of the major vendors in the global clinical trials market?
7. What modes and strategic moves are considered suitable for entering the global clinical trials market?

Main topics covered:

1. Preface

2. Research methodology

3. Executive Summary

4. Market Overview

5. Market Overview
5.1. Market dynamics
5.1.1. Drivers
5.1.1.1. Growing prevalence of diseases
5.1.1.2. Towards patient-centered clinical trials
5.1.1.3. Improved clinical pathways thanks to the consolidation of CROs
5.1.1.4. Increase in R&D expenditure of the pharmaceutical and biopharmaceutical industry
5.1.1.5. Increased focus on drug development
5.1.1.6. Globalization of clinical trials and harmonization of regulations
5.1.2. Constraints
5.1.2.1. Shortage of qualified clinical research professionals
5.1.2.2. Increased cost of drug development and clinical trials
5.1.3. Opportunities
5.1.3.1. Demand for Clinical Trials in Emerging Economies
5.1.3.2. Outsourcing of clinical trial activity
5.1.3.3. Increased focus on the development and commercialization of generics and biologics
5.1.3.4. Regulatory approvals in emerging markets
5.1.4. Challenges
5.1.4.1. Strict regulations for patient registration
5.1.4.2. Cross-border logistical challenges Difficult Clinical trials
5.2. Cumulative impact of COVID-19

6. Clinical Trials Market, By Design
6.1. introduction
6.2. Interventional study
6.2.1. Adaptive clinical trial
6.2.2. Non-randomized control trial
6.2.3. Randomized control trial
6.3. Observational study
6.3.1. Case-control study
6.3.2. Cohort study
6.3.3. Cross-sectional study
6.3.4. Ecological study

7. Clinical Trials Market, By Phase
7.1. introduction
7.2. Phase I
7.3. Stage II
7.4. Phase III
7.5. Stage IV

8. Clinical Trials Market, By Indication
8.1. introduction
8.2. Autoimmune/Inflammation
8.3. Cardiovascular
8.4. CNS status
8.5. Diabetes
8.6. Infectious diseases
8.7. Obesity
8.8. Oncology
8.9. pain management

9. Americas Clinical Trials Market
9.1. introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States

10. Asia Pacific Clinical Trials Market
10.1. introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand

11. Europe, Middle East & Clinical Trials Market in Africa
11.1. introduction
11.2. France
11.3. Germany
11.4. Italy
11.5. Netherlands
11.6. Qatar
11.7. Russia
11.8. Saudi Arabia
11.9. South Africa
11.10. Spain
11.11. United Arab Emirates
11.12. UK

12. Competitive landscape
12.1. FPNV positioning matrix
12.1.1. Quadrants
12.1.2. Business strategy
12.1.3. Product Satisfaction
12.2. Market Ranking Analysis
12.3. Market share analysis, by key player
12.4. Competitive scenario
12.4.1. Merger & Acquisition
12.4.2. Agreement, collaboration and partnership
12.4.3. Launching and improving new products
12.4.4. Investment & Financing
12.4.5. Reward, recognition and expansion

13. Enterprise Usability Profiles
13.1. Accell Clinical Research, LLC
13.2. Atlant Clinic Ltd.
13.3. Charles River International Laboratories, Inc.
13.4. Clinipace
13.5. Eli Lilly and company
13.6. API icon
13.7. IQVIA Holdings, Inc.
13.8. Novo Nordisk A/S
13.9. Parexel International Corporation
13.10. Pfizer Inc.
13.11. ProPharma Group Holdings, LLC
13.12. SGS S.A.
13.13. SIRO Clinpharm Private Limited
13.14. Syneos Health, Inc.
13.15. Thermo Fisher Scientific Inc.
13.16. Wuxi AppTec Inc.

14. Appendix

For more information on this report, visit https://www.researchandmarkets.com/r/nwc0qc

Media Contact:

Research and Markets
Laura Woodsenior
[email protected]

For EST office hours, call +1-917-300-0470
For USA/CAN call toll free +1-800-526-8630
For GMT office hours call +353-1-416-8900

US Fax: 646-607-1907
Fax (outside the US): +353-1-481-1716

Quote Show original content:https://www.prnewswire.com/news-releases/global-clinical-trials-market-research-report-to-2026—featuring-accell-clinical-research-clinipace-and-icon-plc-among- others-301517673.html

SOURCE Research and Markets

Comments are closed.